Vaxart Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Steven Lo
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 21.40% |
| CEO tenure | 2yrs |
| CEO ownership | 1.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jun 20
Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop
Feb 25Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%
Jan 04Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding
Nov 16There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump
Aug 20An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued
Jun 15Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
Nov 08Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely
Jun 30Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis
Sep 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$16m |
| Sep 30 2025 | n/a | n/a | -US$51m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$474k | -US$67m |
Compensation vs Market: Steven's total compensation ($USD2.21M) is above average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Insufficient data to compare Steven's compensation with company performance.
CEO
Steven Lo (58 yo)
Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$2.21m | 1.13% $ 1.8m | |
| Senior VP & Chief Scientific Officer | 16.1yrs | US$1.16m | 0.41% $ 667.4k | |
| Chief Medical Officer | 4.6yrs | US$1.21m | 0.10% $ 167.3k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | less than a year | no data | no data | |
| Senior VP & General Counsel | 4.1yrs | no data | 0.33% $ 537.2k | |
| Senior Vice President of Human Resources | 1.2yrs | no data | no data | |
| Senior Vice President of Clinical Development & Project Management | 6yrs | no data | no data | |
| Senior Vice President of Quality | 5.2yrs | no data | no data |
Experienced Management: VXRT's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2yrs | US$2.21m | 1.13% $ 1.8m | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Independent Director | 3.6yrs | US$143.78k | 0.033% $ 54.7k | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Independent Director | 4.9yrs | US$146.98k | 0.013% $ 20.9k | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Lead Independent Director | 3.6yrs | US$94.76k | 0.045% $ 73.4k | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 4.6yrs | no data | no data |
Experienced Board: VXRT's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 12:19 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| null null | Oppenheimer & Co. Inc. |